EANS-News: DEWB Investment Holding NOXXON Confirms Total Capital Raise of EUR35m

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Berlin, Germany, 12 October 2010 (euro adhoc) - NOXXON Pharma AG
(website) announced today that in addition to the financing of EUR33m
which was recently announced on 27 May 2010 (see press release), it
has concluded a further capital raise of EUR2m which brings the total
amount raised in this series D financing to EUR35m in aggregate.

The new investors who elected to participate in this financing round include CD
Ventures and other private investors.

Iain Buchanan, CEO of NOXXON Pharma AG, commented: "We are pleased to welcome
new investors to NOXXON´s shareholder base and to conclude this enhanced round
of financing. The company is poised to enter a new phase in its growth as the
main assets progress in clinical development. Maintaining a strong balance sheet
is essential as we look to build value."

General contact:

Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email: edelabre@noxxon.com
Website: http://www.noxxon.com

About NOXXON NOXXON Pharma AG is a biotechnology company developing a
promising new class of therapeutics called Spiegelmers, which are
oligonucleotides made from the L-stereoisomer of RNA. Spiegelmers can
be engineered to bind specifically to a precisely defined biological
target and have been shown to be potent inhibitors. Clinical and
pre-clinical studies of Spiegelmers to date have shown them to be
exceptionally safe, well-tolerated, biologically stable and
non-immunogenic. NOXXON has three programs in development, two of
which have successfully completed their first Phase I clinical
studies. The company has approximately 60 employees based at its
headquarters in Berlin. NOXXON´s investors are NGN Capital, TVM
Capital, Sofinnova Partners, Edmond de Rothschild Investment
Partners, Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft
(DEWB), Seventure Partners, The Dow Chemical Company, Dieckell Group,
Oppenheim Asset Management Services, IBG Risikokapitalfonds, VC Fonds
Berlin, CD Ventures and others.

About Spiegelmers® Spiegelmers® (L-stereoisomer RNA oligonucleotides)
are chemical entities based on synthetic mirror-image
oligonucleotides which are highly selective for their pharmacological
target and potent inhibitors of target function. They combine the
benefits of small molecule drugs and biopharmaceuticals. Due to their
unique mirror-image configuration Spiegelmers® are not metabolized
and do not hybridize with native nucleic acids. Spiegelmers® also do
not activate the innate immune response via toll-like receptors and
showed an exceptionally favorable immunogenicity profile in
pre-clinical testing.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marco Scheidler

Tel.: +49 (0) 3641 573-3600

E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Börsen: Berlin / free trade
Stuttgart / free trade
München / free trade
Frankfurt / Open Market / Entry Standard